GlassScriptPhysician profile
John P Gillespie
NPI 1609984475
$2,348.46
in general payments reported to CMS, 2019-2025
30 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $418 · 2021: $260 · 2022: $324 · 2023: $268 · 2024: $241 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $541.27 | 2019-2023 | Myrbetriq |
| Sanofi-Aventis U.S. LLC | $253.49 | 2019-2023 | |
| Amgen INC. | $160.98 | 2019-2025 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $158.02 | 2019-2020 | |
| Abbvie INC. | $154.34 | 2022-2023 | |
| Axsome Therapeutics, INC. | $113.40 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $108.12 | 2020-2025 | Mounjaro |
| Novo Nordisk INC | $84.85 | 2019-2025 | Ozempic |
| Alkermes, INC. | $83.20 | 2024-2025 | Lybalvi, Aristada |
| Pfizer INC. | $76.52 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.43 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $64.82 | 2022-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $61.37 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.06 | 2023-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $45.01 | 2025 | Fanapt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $36.12 | 2024 | Gemtesa |
| Radius Health, INC. | $30.29 | 2019-2020 | |
| Orexo US, INC. | $29.40 | 2022 | |
| Merck Sharp & Dohme LLC | $27.09 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $26.05 | 2020-2023 | Breztri |
| Insulet Corporation | $24.03 | 2023 | Omnipod |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.50 | 2024 | |
| Tris Pharma INC | $20.32 | 2023 | Dyanavel Xr |
| Lundbeck LLC | $19.89 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.37 | 2023 | Jornay Pm |
| Almatica Pharma LLC | $17.15 | 2024 | Loreev Xr |
| Harmony Biosciences LLC | $16.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.29 | 2019 | |
| Glaxosmithkline, LLC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.